Ann: Clinical Trial Update, page-4

"unblinded data released after 3 month treatment : End Sept 2018"

I am thinking August.

But if we use that line there will be enough data there for interested parties. Much contact can be done before that date, so maybe the figures might be the last step before signing.

It's a very commercial product (assuming it works). Data suggests it does and that there is much reduced pain - which is a selling point on it's own.

If this company had $10m more in the bank I think the market cap would be $30m more. But this low market cap gives investors a cheap entry for a product deep into a phase 2 trial. That's unusual.

I do expect a run on the shares upwards as we get near completion, but that still might be a month or two away.

Many biotechs are booming, as the sector is getting re-rated following srx, vla and other takeovers. But ftt is still in it's winter sleep (US time).